The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Partial Response and Nonresponse to Antidepressant Therapy: Current Approaches and Treatment Options
Abstract
BACKGROUND: Response to antidepressant drug therapy is less than optimal for a considerable proportion of depressed patients; at present, however, few data exist to guide their rational therapeutic management. This review describes general principles for the management of such patients. This review is the result of an expert roundtable meeting convened to review published clinical data and clinical experience and provide clinicians with evidence-based principles on the management of patients who fail to respond optimally to initial antidepressant therapy. ROUNDTABLE FINDINGS: Failure to respond may be defined as a < 25% decrease on an accepted symptom rating scale such as the Montgomery-Asberg Depression Rating Scale (MADRS) or the Hamilton Rating Scale for Depression (HAM-D) in a patient who has received an adequate dosage for 4 weeks. In these patients, a neuropharmacologic rationale exists to switch to an agent with a different mode of action or a dual action. Partial response may be defined as 6 to 8 weeks at an adequate dosage and 25% to 50% decrease in MADRS or HAM-D score. In these patients, dose escalation should be considered, followed by augmentation and switching strategies. For augmentation, knowledge of neuropharmacology may allow prediction of which second agent will potentiate or complement the action of the first agent; it may also permit the prediction of potential safety concerns. CONCLUSIONS OF THE PANEL: On the basis of a review of the medical literature and clinical experience regarding patients with partial response or nonresponse to antidepressant drug therapy, it appears that simultaneous targeting of both the noradrenergic and serotonergic systems is one of the most effective augmentation strategies. Switching to an agent of a different class is probably optimal for those patients who fail to respond to first-line therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrence after recovery from major depressive disorder during 15 years of observational follow-up
Mueller, T. I., Leon, A. C., Keller, M. B., Solomon, D. A., Endicott, J., Coryell, W., Warshaw, M., & Maser, J. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1000 · Cited by 897
Venlafaxine for Treatment-Resistant Unipolar Depression
NIERENBERG, A. A., FEIGHNER, J. P., RUDOLPH, R., COLE, J. O., & SULLIVAN, J. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199412000-00008 · Cited by 198
Cited by
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707253 · Cited by 694
Keller, M. B. (2003) · JAMA · doi:10.1001/jama.289.23.3152 · Cited by 388
Somatic symptoms in depression
Kapfhammer, H.-P. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/hpkapfhammer · Cited by 320
Ruhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1203 · Cited by 230
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
Self-citationBielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Keitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108
Self-citationOpiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy
Nyhuis, P. W., Gastpar, M., & Scherbaum, N. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818638a4 · Cited by 90
Self-citationCognitive therapy for anxious depression in STAR(*) D: what have we learned?
Farabaugh, A., Alpert, J., Wisniewski, S. R., Otto, M. W., Fava, M., Baer, L., Perlis, R., Friedman, E., Nyer, M., Bitran, S., et al. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.04.029 · Cited by 52
Dose-response relationship of recent antidepressants in the short-term treatment of depression
Berney, P. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/pberney · Cited by 39
Heiligenstein, J. H., Hoog, S. L., Wagner, K. D., Findling, R. L., Galil, N., Kaplan, S., Busner, J., Nilsson, M. E., Brown, E. B., & Jacobson, J. G. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.207 · Cited by 39
Bschor, T., Ritter, D., Winkelmann, P., Erbe, S., Uhr, M., Ising, M., & Lewitzka, U. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027613 · Cited by 23
“In accordance with established criteria [50,51], patients were classified as responders if their HDRS21-score showed a decrease of 50% or more in the course of the four-week-study and remission was defined as a HDRS21-score of 7 or less on day 28.”
MethodStrategic use of new generation antidepressants for depression: SUN(^_^)D study protocol
Furukawa, T. A., Akechi, T., Shimodera, S., Yamada, M., Miki, K., Watanabe, N., Inagaki, M., & Yonemoto, N. (2011) · Trials · doi:10.1186/1745-6215-12-116 · Cited by 23
Kitzlerová, E., Fišar, Z., Lelková, P., Jirák, R., Zvěřová, M., Hroudová, J., Manukyan, A., Martásek, P., & Raboch, J. (2018) · Medical Science Monitor · doi:10.12659/msm.907202 · Cited by 21
“Thus, MDD patients were subgrouped according to response to treatment as “responders” (defined as >50% improvement in HRSD score compared to baseline) and “nonresponders” [114].”
MethodReddy, S., Fayyad, R., Edgar, C. J., Guico-Pabia, C. J., & Wesnes, K. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116631649 · Cited by 17
Chen, I.-P., Huang, C.-C., Huang, H.-C., Yang, F.-P. G., Ko, K.-T., Lee, Y.-T., Sun, F.-J., & Liu, S.-I. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912430 · Cited by 13
“The secondary outcomes included the change of the HAMD-17 total score from baseline to different visits, the rate of response (proportion of patients with ≥50% reductions of the HAMD-17 score) [27], and the rate of remission (defined as HAMD-17 score ≤ 7) [28].”
Background
Metadata
- Authors
- Hirschfeld, R. M. A., Montgomery, S. A., Aguglia, E., Amore, M., Delgado, P. L., Gastpar, M., Hawley, C., Kasper, S., Linden, M., Massana, J., Mendlewicz, J., Moller, H.-J., Nemeroff, C. B., Saiz, J., Such, P., Torta, R., & Versianix, M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-09-15
- Volume
- 63
- Issue
- 9
- Pages
- 826-837
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1994664270
- Cited by
- 193
- References
- 2
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.